Yuhan Corporation
000100
Clasificación en acciones
#3833
Yuhan Corporation, a prominent South Korean pharmaceutical firm established in... Yuhan Corporation, a prominent South Korean pharmaceutical firm established in 1926 and headquartered in Seoul, specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and intermediates for both domestic and international markets. Its extensive product portfolio encompasses a wide array of prescription pharmaceuticals (ETC), addressing therapeutic areas such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, and hormonal therapies. Notable offerings include Revanex, an acid pump antagonist designed for treating peptic ulcers and gastritis-related mucosal injury. Beyond prescription drugs, Yuhan Corporation provides a diverse range of over-the-counter (OTC) medications, including vitamins, mineral supplements, hepatopathy treatments, tonics, and drugs for respiratory, alimentary, dermatological, and pain relief applications. The company also extends its reach into consumer health and household goods, producing items like bleaches, detergents, pesticides, and oral care products. Further diversifying its operations, Yuhan is involved in the dental sector, supplying implants, equipment, consumables, and dental care solutions, and manufactures veterinary medical supplies for livestock, aquatic species, and companion animals. Additionally, it offers contract manufacturing services to other businesses.
Precio por acción
$63.22
Capitalización bursátil
$4.27B
Cambio (1 día)
-3.12%
Cambio (1 año)
-23.57%
País
KR
Comercio Yuhan Corporation (000100)
Categoría
Healthcare
Ganancias de Yuhan Corporation (000100)
Ganancias en Jun 2026 TTM: $205.87M
Secondo gli ultimi rapporti finanziari di Yuhan Corporation, gli utili attuali della società sono $205.87M. Nel 2024, la società ha registrato un utile di $41.79M, una disminución en comparación con agli utili del 2023, che erano di $104.14M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Yuhan Corporation desde 2007 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $205.87M | 33.56% |
| 2025 | $154.14M | 268.88% |
| 2024 | $41.79M | -59.88% |
| 2023 | $104.14M | 38.44% |
| 2022 | $75.22M | -29.06% |
| 2021 | $106.03M | -52.01% |
| 2020 | $220.97M | 364.61% |
| 2019 | $47.56M | -40.76% |
| 2018 | $80.28M | -40.96% |
| 2017 | $135.98M | -19.98% |
| 2016 | $169.93M | 18.62% |
| 2015 | $143.25M | 35.02% |
| 2014 | $106.09M | 4.27% |
| 2013 | $101.75M | 1.19% |
| 2012 | $100.55M | 9.06% |
| 2011 | $92.20M | -27.70% |
| 2010 | $127.53M | 8.26% |
| 2009 | $117.80M | 4.84% |
| 2008 | $112.36M | 0.30% |
| 2007 | $112.02M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $3.62B | 1,657.37% |
DE
|
|
| $3.40B | 1,553.97% |
DE
|
|
| $1.72B | 737.24% |
JP
|
|
| $930.30M | 351.89% |
CH
|
|
| $1.69B | 722.21% |
IN
|
